[{"indications": "Indications\u00a0see under Cytokine Modulators above", "name": "ANAKINRA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Cytokine modulators"], "cautions": "Cautions\u00a0predisposition to infection; history of asthma (risk of serious infection); interactions: Appendix 1 (anakinra) Blood disorders\u00a0Neutropenia reported commonly. Monitor neutrophil count before treatment, then every month for 6\r\nmonths, then every 3 months\u2014discontinue\r\nif neutropenia develops. Patients should\r\nbe instructed to seek medical advice if symptoms suggestive of neutropenia\r\n(such as fever, sore throat, infection) develop", "side-effects": "Side-effects\u00a0injection-site reactions; headache; infections,\r\nneutropenia (see also Cautions), and antibody formation; also\r\nreported malignancy", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128232.htm", "doses": ["By subcutaneous injection, adult over 18 years, 100\u00a0mg once daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid; effective contraception\r\nmust be used during treatment"}]